{'fraction_non_alphanumeric': 0.0392156862745098, 'fraction_numerical': 0.012066365007541479, 'mean_word_length': 5.384615384615385, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
13: A NOVEL IMMUNOMODULATORY MODEL TO PREDICT REJECTION OUTCOMES AND INDUCE TOLERANCE IN CTA

Purpose: Despite the advance of immunosuppression in composite tissue allotransplantation (CTA), tolerance remains a distant possibility and immunomodulation may prove to be the key. Induction therapy and cyclosporine A (CsA) are widely used in transplantation, yet this is not tolerogenic. Since CsA blocks interleukin-2 (IL-2) transcription and IL-2 dependent regulation, and Tregs require IL-2 for survival, we hypothesize that adding a long lasting IL-2 fusion protein (IL2/Fc) to anti-lymphocyte serum (ALS) and CsA will enhance immunoregulation and CTA tolerance.